Allergan Sues Sandoz Over Sanctura XR Patents

Law360, New York (January 12, 2011, 6:19 PM EST) -- Allergan Inc. and other companies have accused Sandoz Inc. of infringing four patents for overactive bladder drug Sanctura XR.

Allergan contends in a complaint filed Tuesday in the U.S. District Court for the District of Delaware that Sandoz infringed the patents by filing an abbreviated new drug application for a generic version of the medicine, and could further breach them by making and selling the drug before the patents' expiration dates.

Endo Pharmaceuticals Inc., which co-markets Sanctura in the U.S., and Supernus Pharmaceuticals Inc., which owns...
To view the full article, register now.